Swiss Medica, Inc.

Swiss Medica, Inc.

March 22, 2005 08:51 ET

Swiss Medica's O24 Essential Oil Pain Neutralizer Surpasses 6,000-Store Level



OTC Bulletin Board SYMBOL: SWME

MARCH 22, 2005 - 08:51 ET

Swiss Medica's O24 Essential Oil Pain Neutralizer
Surpasses 6,000-Store Level

TORONTO, ONTARIO--(CCNMatthews - March 22, 2005) - Swiss Medica (OTC
BB:SWME) is pleased to announce that the Company's flagship product, O24
Essential Oil Pain Neutralizer, is now available in more than 6,000
stores across North America.

Swiss Medica President, Grant Johnson is delighted to announce, "We have
added a large number of retailers in the first quarter, including some
of Canada's most familiar names, such as Loblaws, London Drugs, and Jean
Coutu. During the first quarter, we have more than tripled the number of
store shelves where consumers can purchase the O24 pain relief product
in the United States and Canada."

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve
chronic ailments. We increase our market share through focused
distribution strategies in multiple sales channels. Swiss Medica's
mission is to be a world leader in the commercialization of life
enhancing bioscience products that improve quality of lives. Please
visit our websites at and

Swiss Medica's flagship product, the O24™ Essential Oil Pain
Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief
solution has been used, recommended and praised for its fast-acting and
long-lasting benefits by healthcare professionals in the United States,
Canada and in Europe. O24 is widely available throughout Canada in
leading pharmacies and natural food stores. It is currently sold in an
increasing number of pharmacies throughout the United States. Customers
can also visit, for ordering details and store locators
for the nearest pharmacy.

Forward-looking statements in this news release are made pursuant to the
"Safe Harbor" provisions of the United States Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties, including,
without limitation, risks relating to the ability to close transactions
being contemplated, risks related to international sales and potential
foreign currency exchange fluctuations, continued acceptance of Swiss
Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks
detailed from time to time in Swiss Medica's periodic reports filed with
the United States Securities and Exchange Commission and other
regulatory authorities.


Contact Information

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    1 866 485 4243
    Blue Skye PR, Inc.
    Press Contact:
    Sky Wallen
    813 732 6869